|
rs116399066
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs2492965
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs2647006
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
|
30593799 |
2019 |
|
rs2647051
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
|
30593799 |
2019 |
|
rs2856723
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.
|
28921602 |
2018 |
|
rs2978048
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs59888390
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs7262634
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs7332270
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs75707332
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs76755915
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs76810409
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs9380516
|
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
|
22841784 |
2012 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The results showed the significant association of rs12980275</span> polymorphism with treatment response in HCV patients followed by rs12979860 and rs8099917.
|
25652367 |
2015 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The importance of three IL28B single nucleotide polymorphisms (rs8099917, rs12980275 and rs12979860) for HCV genotype 2/3-infected patients is unknown.
|
21112657 |
2011 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IL28B rs12980275 AA genotype is a strong predictor of positive response to IFN therapy in Chinese Han patients with hepatitis C.
|
25852288 |
2015 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In hepatitis C virus genotype 1, the OR (95% CI) for rapid and sustained virological response for the wild-type ss469415590 TT was 9.88 (1.99-48.99) and 7.25 (1.91-27.51), respectively, similar to those found for rs12979860 CC [9.55 (1.93-47.37) and 6.30 (1.71-23.13)] and for rs12980275 AA [9.62 (1.94-47.77] and 7.83 (2.02-30.34)], but higher than for rs8099917 TT [4.8 (1.73-13.33) and 4.75 (2.05-10.98)].
|
24308755 |
2014 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
the Interferon lambda (IFNL) polymorphisms genotypes (rs8099917, rs12979860 and rs12980275) and the presence of mutations in HCV core protein were analyzed in 59 patients with HCC, and also in 50 cirrhotic patients (without HCC).
|
27035616 |
2016 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Haplotype analysis showed that IL28B (rs12980275, rs11881222, rs12979860 and rs8099917) haplotype AACT had a protective effect for HCV infection (OR = 0.52, 95% CI = 0.33-0.83, P = 0.00551).
|
24144988 |
2014 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of the work is to evaluate the predictive power of the rs12979860 IL28B SNP and rs12980275 IL28B SNP for treatment response in Egyptian patients infected with HCV genotype 4.
|
24999753 |
2014 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
AA genotype of rs12980275 was a predictive factor for SVR in HCV patients with PEG-IFN/RBV treatment, especially in HCV genotype 1/4.
|
25769643 |
2015 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis indicated that cholesterol, triglyceride, low-density lipoprotein, 25-hydroxyvitamin D, platelets, duration of hemodialysis, HCV subtypes, IFNL3 rs12979860 TT, IFNL3 rs8099917 GG, IFNL3 rs12980275 GG, and IFNL4 ss469415590 ΔG/ΔG genotypes were associated with OCI.
|
30821879 |
2019 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated predictive factors including HCV RNA, histological findings, IL28B SNP genotypes (rs8099917, rs12979860, and rs12980275), and the effect of treatment regimen and prior treatment history.
|
21112660 |
2011 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Next, a decision tree showed early treatment failure increased from 37.1% to 65.5% when the unfavourable rs12980275 AG/GG and rs10903035 AG/GG genotypes and HCV-RNA≥ 500.000 IU/mL were taken into account in GT1/4 patients.
|
23565619 |
2013 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Independent predictors of SVR were rs12980275 AA (OR 9.68; 3.44-27.18), age <40 years (OR=4.79; 1.50-15.34) and HCV RNA <400 000 IU/mL (OR 2.74; 1.03-7.27) in HCV genotype 1 patients and rs12980275 AA (OR=6.26; 1.98-19.74) and age <40 years (OR 5.37; 1.54-18.75) in the 88 HCV genotype 1 patients without a RVR.
|
21443535 |
2011 |